#	Pagina
attuale pagina	/open-h2020/projects/219925/index.html

Opendata, web and dolomites

LEGACy SIGNED

CeLac and European consortium for a personalized medicine approach to Gastric Cancer

Total Cost €

EC-Contrib. €

Partnership

Views

LEGACy project word cloud

Explore the words cloud of the LEGACy project. It provides you a very rough idea of what is the project "LEGACy" about.

participating medicine location health sexes public levels biology similarly multicentre mortality women northern dietary none america intervention ebv populations disease rates secondary central omics differences urgent death gastric barr helicobacter personalized primary sharp prevention makeup deaths patients globally treatments tumour virus 723 arrival worldwide strains 24 countries conceptual 10 celac gcs bacterium extended largely outcomes model highest south locally cancer databases prognosis molecular histological asian asia genetic lowest legacy standpoint eastern positive incidence plays epidemiological genome gc pylori multiple stage respectively strategies contrast 8 men epidemiology infection revolutionized integrative epstein susceptibility international total vary poorly strategy

Project "LEGACy" data sheet

The following table provides information about the project.

Coordinator	FUNDACION PARA LA INVESTIGACION DEL HOSPITAL CLINICO DE LA COMUNITAT VALENCIANA, FUNDACION INCLIVA Organization address address: AV MENENDEZ PELAYO 4 city: VALENCIA postcode: 46010 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Spain [ES]
Total cost	3˙993˙056 €
EC max contribution	3˙577˙431 € (90%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SC1-2018-Single-Stage-RTD
Funding Scheme	RIA
Starting year	2019
Duration (year-month-day)	from 2019-01-01 to 2022-12-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	FUNDACION PARA LA INVESTIGACION DEL HOSPITAL CLINICO DE LA COMUNITAT VALENCIANA, FUNDACION INCLIVA FUNDACION PARA LA INVESTIGACION DEL HOSPITAL CLINICO DE LA COMUNITAT VALENCIANA, FUNDACION INCLIVA Organization address address: AV MENENDEZ PELAYO 4 city: VALENCIA postcode: 46010 website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (VALENCIA)	coordinator	638˙315.00
2	IPATIMUP - INSTITUTO DE PATOLOGIA E IMUNOLOGIA MOLECULAR DA UNIVERSIDADE DO PORTO PCUP IPATIMUP - INSTITUTO DE PATOLOGIA E IMUNOLOGIA MOLECULAR DA UNIVERSIDADE DO PORTO PCUP Organization address address: RUA JULIO AMARAL DE CARVALHO 45 city: PORTO postcode: 4200 135 website: http://www.ipatimup.pt contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	PT (PORTO)	participant	660˙162.00
3	FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON Organization address address: CALLE NAZARET 115-117 city: BARCELONA postcode: 8035 website: http://www.vhio.net contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (BARCELONA)	participant	550˙000.00
4	STICHTING VUMC STICHTING VUMC Organization address address: DE BOELELAAN 1117 city: AMSTERDAM postcode: 1081 HV website: www.vumc.nl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (AMSTERDAM)	participant	471˙875.00
5	PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE Organization address address: AVENIDA LIBERTADOR BERNARDO O'HIGGINS 340 city: SANTIAGO postcode: 8331150 website: www.uc.cl contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	CL (SANTIAGO)	participant	305˙235.00
6	ANAXOMICS BIOTECH, S.L. ANAXOMICS BIOTECH, S.L. Organization address address: CALLE DIPUTACIO 237, P 1 PTA 1 city: BARCELONA postcode: 8007 website: www.anaxomics.com contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	ES (BARCELONA)	participant	275˙218.00
7	CABALLERO LLANO CARMELO CESAR CABALLERO LLANO CARMELO CESAR Organization address address: FORTIN TOLEDO 524 APT 2 city: ASUNCION postcode: n.a. website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	PY (ASUNCION)	participant	216˙093.00
8	EUROPEAN CANCER PATIENT COALITION EUROPEAN CANCER PATIENT COALITION Organization address address: RUE MONTOYER 40 city: BRUXELLES postcode: 1000 website: www.ecpc-online.org contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	BE (BRUXELLES)	participant	197˙750.00
9	ALEXANDER FLEMING SA ALEXANDER FLEMING SA Organization address address: CARMER 1180 city: BUENOS AIRES postcode: C1426NZ website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	AR (BUENOS AIRES)	participant	131˙625.00
10	UNIVERSITAET LEIPZIG UNIVERSITAET LEIPZIG Organization address address: RITTERSTRASSE 26 city: LEIPZIG postcode: 4109 website: www.uni-Ieipzig.de contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	DE (LEIPZIG)	participant	131˙156.00
11	Instituto Nacional de Cancerología Instituto Nacional de Cancerología Organization address address: Av. San Fernando 22 city: MEXICO postcode: 1480 website: www.incan.edu.mx contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	MX (MEXICO)	participant	0.00

Map

Project objective

Globally, gastric cancer (GC) is the third leading cause of cancer death in both sexes worldwide (723,000 deaths, 8.8% of the total). The highest estimated mortality rates are in Eastern Asia (24 per 100,000 in men, 9.8 per 100,000 in women), the lowest in Northern America (2.8 and 1.5, respectively). High mortality rates are also present in both sexes in Central and Eastern Europe, and in Central and South America. None strategies have improved prognosis in locally advanced stage III and IV GC. Therefore, an urgent intervention is needed. Epidemiological and molecular features of GCs can vary widely according to their histological type, location and genetic makeup of the tumour. The reasons behind these differences are multiple and complex and may include genetic susceptibility, strains of the bacterium Helicobacter pylori (H. pylori) and dietary factors. In particular, H. pylori infection plays a relevant role in GC incidence. Similarly, about 10% of GC patients are positive for the infection of the Epstein Barr Virus (EBV) . Most studies and current international databases on late-stage/advanced GC are largely based on Asian populations, in sharp contrast tumour biology and genome of EU and CELAC countries is poorly known. From a public health standpoint, prevention can be conducted at three levels: primary, secondary, and for improving outcomes at the advanced stage of disease. In recent years, the arrival of personalized medicine has revolutionized available treatments for cancer patients. The primary aim of LEGACY project is to improve GC outcomes by applying personalized medicine at the three levels of prevention: in EU and CELAC countries participating in this multicentre case-control study based on an “omics integrative epidemiology” conceptual model as a strategy to be extended worldwide.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LEGACY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LEGACY" are provided by the European Opendata Portal: CORDIS opendata.